SRES-620-119
Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S716; text: CR S711)
Sponsored by John Barrasso (R-WY)
What it does
This resolution designates February 28, 2026, as "Rare Disease Day." It recognizes the importance of raising awareness about rare diseases, encouraging early and accurate diagnosis, and supporting national and global research efforts to develop treatments and cures. The resolution does not create new law, appropriate funds, or impose any requirements on any person or agency.
Who benefits
The approximately 30 million Americans living with one of more than 10,000 known rare diseases may benefit from increased public awareness. Patient advocacy organizations focused on rare diseases gain a formal congressional acknowledgment. Researchers and pharmaceutical companies working on orphan drugs may benefit from heightened visibility. Children with rare diseases, who represent a significant share of those affected, are specifically recognized.
Who is hurt
No group is directly or materially harmed by this resolution. As a purely commemorative measure, it imposes no costs, restrictions, or obligations on any individual, organization, or government entity.
Supporters argue
Supporters argue that approximately 95 percent of rare diseases still lack an FDA-approved treatment, and that public awareness is a necessary precursor to increased research funding and policy attention. They contend that formal congressional recognition reinforces the importance of programs like the Orphan Drug Act — which has driven significant treatment advances since 1983 — and encourages continued investment in a population of 30 million Americans who are often overlooked due to the small size of individual patient communities.
Opponents argue
Opponents might argue that commemorative resolutions consume limited legislative floor time without producing binding policy outcomes, and that the underlying challenges — such as the 95 percent of rare diseases lacking approved treatments — require substantive legislation, not symbolic recognition. They could contend that passing resolutions without accompanying funding or regulatory action may give the appearance of addressing a problem while leaving the structural barriers facing rare disease patients unchanged.